INCOME TAXES (Effective Tax Rate Reconciliation) (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
U.S Earnings/(Loss) before income taxes	$ (135)	$ (271)	$ 4,336
Non-U.S. Earnings before income taxes	3,026	2,611	2,645
Earnings Before Income Taxes	2,891	2,340	6,981
Effective Income Tax Rate Reconciliation, Amount [Abstract]
U.S. statutory rate, Amount	1,012	819	2,443
Non-tax deductible annual pharmaceutical company fee, Amount	63	90	80
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland	(620)	(688)	(593)
State and local taxes (net of valuation allowance), Amount	25	20	33
U.S. Federal, state and foreign contingent tax matters, Amount	134	66	(161)
U.S. Federal research and development tax credit, Amount	(181)		(69)
U.S. tax effect of capital losses, Amount		(392)
Foreign and other, Amount	(122)	(76)	(12)
Provision for/(Benefit from) Income Taxes	311	(161)	1,721
Tax benefit from finalizing prior year U.S. income tax return		54
Retroactive reinstatement of the 2012 research and development tax credit recognized in 2013	$ 82
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. statutory income tax rate	35.00%	35.00%	35.00%
Non-tax deductible annual pharmaceutical company fee, Rate	2.20%	3.80%	1.20%
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland, Rate	(21.40%)	(29.40%)	(8.50%)
State and local taxes (net of valuation allowance), Rate	0.90%	0.90%	0.50%
U.S. Federal, state and foreign contingent tax matters, Rate	4.60%	2.80%	(2.30%)
U.S. Federal research and development tax credit, Rate	(6.30%)		(1.00%)
U.S. tax effect of capital losses, Rate		(16.70%)
Foreign and other, Rate	(4.20%)	(3.30%)	(0.20%)
Effective income tax/(benefit) rate	10.80%	(6.90%)	24.70%